{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T06:01:14Z","timestamp":1781157674460,"version":"3.54.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Chem."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Major depressive disorder (MDD) in adolescents remains a significant public health challenge. Treatment-resistant depression (TRD) affects a substantial proportion of cases and is associated with chronic symptoms, comorbidities, and elevated suicide risk. Standard treatments frequently show limited success, leading to off-label consideration of atypical antipsychotics as augmentation agents. Risperidone has shown promise in adults, but data in adolescents are limited. This retrospective study evaluates clinical outcomes of risperidone augmentation in adolescent TRD, complemented by\n                      <jats:italic>in silico<\/jats:italic>\n                      modeling of potential molecular interactions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective data from 50 adolescents (aged 12\u201318) with DSM-5 MDD and TRD (non-response to \u22652 antidepressants) were analyzed. Risperidone (0.25\u20132\u00a0mg\/day) was added to ongoing antidepressants for \u22658\u00a0weeks. Efficacy was assessed via changes in CDRS-R and HAM-D scores, response (\u226550% reduction), and remission rates. Adverse events were documented. In silico molecular docking and 200 ns MD simulations explored risperidone\u2019s interactions with selected targets (DRD2, 5-HT2AR, SERT, and NMDA) using available PDB structures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Mean age was 15.4\u00a0years; 56% female. Depression scores improved: CDRS-R decreased from 64.3 to 38.9 (mean change \u221225.4 points), HAM-D from 23.6 to 12.1 (mean change \u221211.5 points). Response rates were 64% (CDRS-R) and 60% (HAM-D); remission rates were 40% and 36%, respectively. Baseline severity was associated with response (OR 1.22, p = 0.01). Common adverse events (mostly mild-moderate) included weight gain (24%), sedation (16%), and EPS (12%). Docking and MD simulations suggested favorable binding, particularly to DRD2 and 5-HT2AR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this retrospective cohort, risperidone augmentation was associated with symptom improvement in adolescents with TRD and showed an acceptable short-term safety profile. In silico analyses suggest potential interactions with monoaminergic receptors that may contribute to its effects. These findings are hypothesis-generating and require confirmation in prospective randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fchem.2026.1848435","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:47:07Z","timestamp":1781156827000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A retrospective and in silico study on the augmentation of risperidone in the treatment of adolescent treatment-resistant depression: efficacy evaluation, adverse reaction analysis, and molecular mechanistic insights"],"prefix":"10.3389","volume":"14","author":[{"given":"Xiaoli","family":"Shen","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Heping Hospital Affiliated to Changzhi Medical College","place":["Changzhi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Heping Hospital Affiliated to Changzhi Medical College","place":["Changzhi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/s0149-7634(03)00005-8","article-title":"Trajectories of brain development: point of vulnerability or window of opportunity?","volume":"27","author":"Andersen","year":"2003","journal-title":"Neurosci. Biobehav Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.9758\/cpn.2018.16.1.57","article-title":"Efficacy and safety profile of risperidone long-acting injection in adolescents in a real-life setting","volume":"16","author":"Ardic","year":"2018","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.4088\/jcp.v69n0805","article-title":"Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study","author":"Ballenger","year":"2010","journal-title":"Year Book Psychiatry & Appl. Ment. Health"},{"key":"B5","first-page":"55","article-title":"Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia","volume":"4","author":"Bishop","year":"2008","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"B6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nrn2353","article-title":"The social brain in adolescence","volume":"9","author":"Blakemore","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.9740\/mhc.2024.02.010","article-title":"Antipsychotics in child and adolescent patients with major depressive disorder: a retrospective analysis of prescribing patterns","volume":"14","author":"Dauchot","year":"2024","journal-title":"Ment. Health Clin."},{"key":"B8","volume-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM-5\u2122","year":"2013"},{"key":"B9","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/jcpp.13202","article-title":"Annual research review: defining and treating pediatric treatment-resistant depression","volume":"61","author":"Dwyer","year":"2020","journal-title":"J. Child. Psychol. Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1176\/appi.ajp.2010.09040552","article-title":"Treatment of resistant depression in adolescents (TORDIA): week 24 outcomes","volume":"167","author":"Emslie","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0011-393X(03)00006-7","article-title":"Risperidone in children and adolescents with conduct disorder: a single-center, open-label study","volume":"64","author":"Ercan","year":"2003","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"B12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1002\/jcc.23354","article-title":"CHARMM36 all-atom additive protein force field: validation based on comparison to NMR data","volume":"34","author":"Huang","year":"2013","journal-title":"J. Comput. Chem."},{"key":"B14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s43556-024-00205-y","article-title":"Treatment-resistant depression: molecular mechanisms and management","volume":"5","author":"Kajumba","year":"2024","journal-title":"Mol. Biomed."},{"key":"B15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jpsychires.2008.05.003","article-title":"A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression","volume":"43","author":"Keitner","year":"2009","journal-title":"J. Psychiatric Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"593","DOI":"10.7326\/0003-4819-147-9-200711060-00003","article-title":"Risperidone for treatment-refractory major depressive disorder: a randomized trial","volume":"147","author":"Mahmoud","year":"2007","journal-title":"Ann. Intern Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1056\/NEJMoa013171","article-title":"Risperidone in children with autism and serious behavioral problems","volume":"347","author":"McCracken","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3389\/fpsyt.2024.1417977","article-title":"Major challenges in youth psychopathology: treatment-resistant depression. A narrative review","author":"Menculini","year":"2024","journal-title":"Front. Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.jaac.2010.05.017","article-title":"Lifetime prevalence of mental disorders in U.S. adolescents: results from the national comorbidity survey Replication--Adolescent supplement (NCS-A)","volume":"49","author":"Merikangas","year":"2010","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.molmed.2025.12.003","article-title":"Major depressive disorder: susceptibility, underlying mechanisms, and emerging therapies","volume":"32","author":"Onisiforou","year":"2026","journal-title":"Trends Mol. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/jcpp.12381","article-title":"Annual research review: a meta-analysis of the worldwide prevalence of mental disorders in children and adolescents","volume":"56","author":"Polanczyk","year":"2015","journal-title":"J. Child. Psychol. Psychiatry"},{"key":"B22","first-page":"218","article-title":"Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth","volume":"20","author":"Pringsheim","year":"2011","journal-title":"J. Can. Acad. Child. Adolesc. Psychiatry"},{"key":"B23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000518098","article-title":"Molecular mechanisms associated with antidepressant treatment on major depression","volume":"7","author":"Ramos-da-Silva","year":"2021","journal-title":"Complex Psychiatry"},{"key":"B24","first-page":"21","article-title":"Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders","volume":"69","author":"Sikich","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"B25","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1089\/cap.2020.0008","article-title":"Treatment-resistant depression in adolescents: clinical features and measurement of treatment resistance","volume":"30","author":"Strawn","year":"2020","journal-title":"J. Child. Adolesc. Psychopharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"B27","doi-asserted-by":"publisher","first-page":"6281","DOI":"10.1021\/acs.jctc.1c00645","article-title":"gmx_MMPBSA: a new tool to perform end-state free energy calculations with GROMACS","volume":"17","author":"Vald\u00e9s-Tresanco","year":"2021","journal-title":"J. Chem. Theory Comput."},{"key":"B28","doi-asserted-by":"publisher","first-page":"W296","DOI":"10.1093\/nar\/gky427","article-title":"SWISS-MODEL: homology modelling of protein structures and complexes","volume":"46","author":"Waterhouse","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1574574","article-title":"Advances in the prevalence and treatment of depression for adolescents: a review","volume":"16","author":"Yin","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e1512","DOI":"10.1002\/hsr2.1512","article-title":"Clinical implication of children's depression rating scale-revised score: linking the children's depression rating scale-revised score and clinical global impression using patients data from clinical trials","volume":"6","author":"Yoshimatsu","year":"2023","journal-title":"Health Sci. Rep."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1021\/acschemneuro.6b00074","article-title":"Two binding geometries for risperidone in dopamine D3 receptors: insights on the fast-off mechanism through docking, quantum biochemistry, and molecular dynamics simulations","volume":"7","author":"Zanatta","year":"2016","journal-title":"ACS Chem. Neurosci."}],"container-title":["Frontiers in Chemistry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2026.1848435\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:47:10Z","timestamp":1781156830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2026.1848435\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":31,"alternative-id":["10.3389\/fchem.2026.1848435"],"URL":"https:\/\/doi.org\/10.3389\/fchem.2026.1848435","relation":{},"ISSN":["2296-2646"],"issn-type":[{"value":"2296-2646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"article-number":"1848435"}}